Skip to content
Biodatica
Start free

Otsuka Pharmaceutical Co., Ltd.

Tokyo

OncologyPhase IIIListed · OTSKY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

4mo agoTrial registeredFeb 25, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Momentum 81 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Oct 1, 2025

    Atopic Dermatitis (AD) · NOT_YET_RECRUITING · sponsor: Otsuka Pharmaceutical Co., Ltd. · A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

    ClinicalTrials.gov · NCT07173478 (opens the source filing in a new tab)

  2. Trial

    PHASE2/PHASE3 registered

    Sep 3, 2025

    Attention-Deficit Hyperactivity Disorder(ADHD) · RECRUITING · sponsor: Otsuka Pharmaceutical Co., Ltd. · A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

    ClinicalTrials.gov · NCT07086313 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Sep 1, 2025

    Atopic Dermatitis (AD) · NOT_YET_RECRUITING · sponsor: Otsuka Pharmaceutical Co., Ltd. · A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

    ClinicalTrials.gov · NCT07184645 (opens the source filing in a new tab)

  4. Trial

    PHASE2/PHASE3 registered

    Apr 30, 2025

    Attention Deficit Hyperactivity Disorder (ADHD) · RECRUITING · sponsor: Otsuka Pharmaceutical Co., Ltd. · Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

    ClinicalTrials.gov · NCT06931080 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Feb 18, 2021

    Multiple Myeloma (MM) · ACTIVE_NOT_RECRUITING · sponsor: Otsuka Pharmaceutical Co., Ltd. · Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT04649073 (opens the source filing in a new tab)

  6. Trial

    PHASE1/PHASE2 registered

    Jul 14, 2020

    Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL) · TERMINATED · sponsor: Otsuka Pharmaceutical Co., Ltd. · A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

    ClinicalTrials.gov · NCT04362007 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources